Paracentral and Cecocentral Scotomas after Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment
Vlad Matei, MD  |  November 16, 2020
Continue Reading
Joshua D. Levinson, MD  |  November 10, 2020
Continue Reading
Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial
Judy Chen, MD  |  November 2, 2020
Continue Reading
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial
Katherine E. Talcott, MD  |  October 21, 2020
Continue Reading
Vitrectomy as an Aerosol-Generating Procedure in the Time of COVID-19: The VAPOR Study
Prethy Rao, MD MPH  |  October 10, 2020
Continue Reading
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration
Maxwell S. Stem, MD  |  September 30, 2020
Continue Reading
Timing of Peak Vision Gains in Patients with Neovascular Age-related Macular Degeneration Treated with Ranibizumab
Mehnaz Khan, MD  |  September 18, 2020
Continue Reading
Management of Infantile and Childhood Retinopathies: Optimized Pediatric Pars Plana Vitrectomy Sclerotomy Nomogram
Edward H. Wood, MD  |  September 10, 2020
Continue Reading
Primary Retinal Detachment Outcomes Study Report Number 2: Phakic Retinal Detachment Outcomes
Brian C. Toy, MD  |  September 1, 2020
Continue Reading
Disease course in patients with pentosan polysulfate sodium–associated maculopathy after drug cessation
Christian J. Sanfilippo, MD  |  August 25, 2020
Continue Reading
Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients
Philip P. Storey, MD  |  August 1, 2020
Continue Reading
Fovea-Sparing Versus Standard Internal Limiting Membrane Peeling for Myopic Traction Maculopathy
Musa R. Abdelaziz, MD  |  July 17, 2020
Continue Reading